About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
The University of Kansas Cancer Center
https://www.kucancercenter.org/
2023 Multidisciplinary Oncology Review
2022
Advances in Hematologic Malignancies and Cellular Therapeutics Symposium
2022 Post San Antonio Review
Videos
2021
2021 Virtual KU Hematology and Medical Oncology Review
2021 Post San Antonio Review
2021 KUMC Virtual Multidisciplinary Oncology Review
2020
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
2020 ASCO Highlights
2019
2019 Post San Antonio Breast Cancer Review
ASH 2019 Review: Current Updates in Hematologic Diseases
2019 Lung Cancer and Head & Neck Cancer Symposium
Hematology & Medical Oncology Review 2019
Lung
Hematologic Malignancies
Gastrointestinal
Head and Neck
Genitourinary
Skin
Palliative
General
Event
2018
ASH: Current Updates in Hematologic Diseases
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
V
SABCS 2019 Highlights on IO in mTNB: IMpassion130 Suggest PD-L1+ Pts Have Better Outcomes w/ Atezolizumab+Chemo, SAFIRO2-IMMUNO Suggests Durvalumab Improves OS
By
KU 2019 Post San Antonio Breast Cancer Review
FEATURING
Virginia Kaklamani
By
KU 2019 Post San Antonio Breast Cancer Review
FEATURING
Virginia Kaklamani
188 views
March 12, 2020
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
2019 Post San Antonio Breast Cancer Review
17:37
KU 2019 Post San Antonio Breast Cancer Review
SABCS 2019 Highlights on Metastatic HER2+ Breast Cancer: Outcomes of…
Feat.
W. Gradishar
11:53
KU 2019 Post San Antonio Breast Cancer Review
SABCS 2019 Highlights on Metastatic HER2+ Breast Cancer Management: …
Feat.
W. Gradishar
10:29
KU 2019 Post San Antonio Breast Cancer Review
SABCS 2019 Highlights on Adjuvant Therapy Options for HER2+ Breast C…
Feat.
W. Gradishar
18:55
KU 2019 Post San Antonio Breast Cancer Review
SABCS 2019 Highlights on Early Stage TNBC: 5-FU Has a Benefit, Neoad…
Feat.
V. Kaklamani
06:40
KU 2019 Post San Antonio Breast Cancer Review
SABCS 2019 Highlights on IO in mTNB: IMpassion130 Suggest PD-L1+ Pts…
Feat.
V. Kaklamani
09:08
KU 2019 Post San Antonio Breast Cancer Review
SABCS 2019 Updates on Breast Cancer Chemoprevention: Anastrozole Sig…
Feat.
T. Mamounas
23:29
KU 2019 Post San Antonio Breast Cancer Review
SABCS 2019 Updates on Early Stage HR+: Oral Formulation S-1 + Adjuva…
Feat.
T. Mamounas
07:01
KU 2019 Post San Antonio Breast Cancer Review
SABCS 2019 Updates on Metastatic HR+ BC: PEARL Suggests Treatment Wi…
Feat.
T. Mamounas
11:46
KU 2019 Post San Antonio Breast Cancer Review
52 y/o With HER2+/HR- De-novo Metastatic BC / 52 y/o With T2N0 HR+/H…
Feat.
A. Kurian,
Q. Khan,
P. Sharma,
V. Kaklamani,
T. Mamounas,
W. Gradishar
11:23
KU 2019 Post San Antonio Breast Cancer Review
46 y/o F With Grade 2, 2.5 cm, NO ER+ Left BC / 40 y/o Premenopausal…
Feat.
A. Kurian,
Q. Khan,
P. Sharma,
V. Kaklamani,
T. Mamounas,
W. Gradishar
08:39
KU 2019 Post San Antonio Breast Cancer Review
55 y/o Diagnosed With T3NO TNBC / 42 y/o With cT2N+ Grade IlTNBC, Re…
Feat.
A. Kurian,
Q. Khan,
P. Sharma,
V. Kaklamani,
T. Mamounas,
W. Gradishar
